George Golumbeski

This profile gathers the share dealings of George Golumbeski across 4 companies, led by Enanta Pharmaceuticals Inc, Shattuck Labs, Inc. and Sage Therapeutics, Inc. The record holds 13 filings, for trades running from 11 February 2019 to 3 June 2026.

Market trades split into 4 purchases (€425k) and 3 sales (€1.9M). Netting one side against the other leaves €1.5M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant and 4 option exercises.

A typical purchase (the median) is worth €93k. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days.

On 5 June 2026 came the latest disclosure, a share grant in Acumen Pharmaceuticals, Inc. The last purchase on record was published on 9 May 2022, which is 1,629 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.